These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

463 related articles for article (PubMed ID: 26825065)

  • 1. Treatment of patients with juvenile idiopathic arthritis (JIA) in a population-based cohort.
    Zamora-Legoff JA; Krause ML; Crowson CS; Muskardin TW; Mason T; Matteson EL
    Clin Rheumatol; 2016 Jun; 35(6):1493-9. PubMed ID: 26825065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort.
    Guzman J; Oen K; Tucker LB; Huber AM; Shiff N; Boire G; Scuccimarri R; Berard R; Tse SM; Morishita K; Stringer E; Johnson N; Levy DM; Duffy KW; Cabral DA; Rosenberg AM; Larché M; Dancey P; Petty RE; Laxer RM; Silverman E; Miettunen P; Chetaille AL; Haddad E; Houghton K; Spiegel L; Turvey SE; Schmeling H; Lang B; Ellsworth J; Ramsey S; Bruns A; Campillo S; Benseler S; Chédeville G; Schneider R; Yeung R; Duffy CM;
    Ann Rheum Dis; 2015 Oct; 74(10):1854-60. PubMed ID: 24842571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response to treatment with intra-articular triamcinolone hexacetonide and triamcinolone acetonide in oligo articular juvenile idiopathic arthritis.
    Harhay R; Jeelani W; Agbor BTA; Hennon T; Wrotniak BH; Abdul-Aziz R
    Pediatr Rheumatol Online J; 2021 Mar; 19(1):36. PubMed ID: 33743721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors determining resistance to conventional disease-modifying anti-rheumatic drug treatment in oligoarticular juvenile idiopathic arthritis.
    Sener S; Aliyev E; Batu ED; Balik Z; Bayindir Y; Cam V; Basaran O; Bilginer Y; Ozen S
    Clin Rheumatol; 2024 Jun; 43(6):2021-2026. PubMed ID: 38683443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children Register.
    Otten MH; Anink J; Prince FH; Twilt M; Vastert SJ; ten Cate R; Hoppenreijs EP; Armbrust W; Gorter SL; van Pelt PA; Kamphuis SS; Dolman KM; Swart JF; van den Berg JM; Koopman-Keemink Y; van Rossum MA; Wulffraat NM; van Suijlekom-Smit LW
    Ann Rheum Dis; 2015 Jul; 74(7):1379-86. PubMed ID: 24641940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucocorticoid treatment in juvenile idiopathic arthritis.
    Batu ED
    Rheumatol Int; 2019 Jan; 39(1):13-27. PubMed ID: 30276425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment prescribing patterns in patients with juvenile idiopathic arthritis (JIA): Analysis from the UK Childhood Arthritis Prospective Study (CAPS).
    Davies R; Carrasco R; Foster HE; Baildam EM; Chieng SEA; Davidson JE; Ioannou Y; Wedderburn LR; Thomson W; Hyrich KL
    Semin Arthritis Rheum; 2016 Oct; 46(2):190-195. PubMed ID: 27422803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of the COVID-19 Pandemic on the Management of Juvenile Idiopathic Arthritis: Analysis of United States Commercial Insurance Data.
    Horton DB; Yang Y; Neikirk A; Huang C; Crystal S; Davidow A; Haynes K; Gerhard T; Rose CD; Strom BL; Parlett L
    J Clin Rheumatol; 2023 Dec; 29(8):388-395. PubMed ID: 37798830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biologics in juvenile idiopathic arthritis: a narrative review.
    Vanoni F; Minoia F; Malattia C
    Eur J Pediatr; 2017 Sep; 176(9):1147-1153. PubMed ID: 28725955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decreasing trend in the incidence of serious pneumonias in Finnish children with juvenile idiopathic arthritis.
    Salonen PH; Salonen JH; Säilä H; Helminen M; Linna M; Kauppi MJ
    Clin Rheumatol; 2020 Mar; 39(3):853-860. PubMed ID: 31732822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-dose methotrexate treatment for oligoarticular juvenile idiopathic arthritis nonresponsive to intra-articular corticosteroids.
    Brik R; Gepstein V; Berkovitz D
    Clin Rheumatol; 2005 Nov; 24(6):612-4. PubMed ID: 15877178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors associated with treatment response to etanercept in juvenile idiopathic arthritis.
    Otten MH; Prince FH; Armbrust W; ten Cate R; Hoppenreijs EP; Twilt M; Koopman-Keemink Y; Gorter SL; Dolman KM; Swart JF; van den Berg JM; Wulffraat NM; van Rossum MA; van Suijlekom-Smit LW
    JAMA; 2011 Dec; 306(21):2340-7. PubMed ID: 22056397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Summary of AHRQ's Comparative Effectiveness Review of Disease-Modifying Antirheumatic Drugs for Children with Juvenile Idiopathic Arthritis.
    McMahan R; Balfe LM; Greene L
    J Manag Care Pharm; 2012; 18(1 Suppl B):1-16. PubMed ID: 22376227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry.
    Schmeling H; Minden K; Foeldvari I; Ganser G; Hospach T; Horneff G
    Arthritis Rheumatol; 2014 Sep; 66(9):2580-9. PubMed ID: 24942886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Macrophage migration inhibitory factor (MIF) and oligoarticular juvenile idiopathic arthritis (o-JIA): association of MIF promoter polymorphisms with response to intra-articular glucocorticoids.
    Vivarelli M; D'Urbano LE; Insalaco A; Lunt M; Jury F; Tozzi AE; Ravelli A; Martini A; Donn R; De Benedetti F
    Clin Exp Rheumatol; 2007; 25(5):775-81. PubMed ID: 18078632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prescribing Patterns and Impact of Factors Associated with Time to Initial Biologic Therapy among Children with Non-systemic Juvenile Idiopathic Arthritis.
    Yue X; Huang B; Hincapie AL; Wigle PR; Qiu T; Li Y; Morgan EM; Guo JJ
    Paediatr Drugs; 2021 Mar; 23(2):171-182. PubMed ID: 33651370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Juvenile idiopathic arthritis managed in the new millennium: one year outcomes of an inception cohort of Australian children.
    Tiller G; Buckle J; Allen R; Munro J; Gowdie P; Cox A; Akikusa J
    Pediatr Rheumatol Online J; 2018 Nov; 16(1):69. PubMed ID: 30413164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biologic treatment response among adults with juvenile idiopathic arthritis: results from the British Society for Rheumatology Biologics Register.
    McErlane F; Foster HE; Davies R; Lunt M; Watson KD; Symmons DP; Hyrich KL
    Rheumatology (Oxford); 2013 Oct; 52(10):1905-13. PubMed ID: 23873820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Juvenile idiopathic arthritis--current and future therapies.
    Kahn P
    Bull NYU Hosp Jt Dis; 2009; 67(3):291-302. PubMed ID: 19852753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and long-term retention of anti-tumour necrosis factor treatment in juvenile and adult patients with juvenile idiopathic arthritis: data from Reuma.pt.
    Mourão AF; Santos MJ; Melo Gomes JA; Martins FM; Mendonça SC; Oliveira Ramos F; Fernandes S; Salgado M; Guedes M; Carvalho S; Costa JA; Brito I; Duarte C; Furtado C; Lopes A; Rodrigues A; Sequeira G; Branco JC; Fonseca JE; Canhão H
    Rheumatology (Oxford); 2016 Apr; 55(4):697-703. PubMed ID: 26672905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.